BlackRock, Inc. Reduces Stake in Solid Biosciences Inc. (SLDB) to 4.7%

On April 27, 2026, BlackRock, Inc. filed a Schedule 13G/A with the SEC, reporting a decrease in its holdings in Solid Biosciences Inc. (SLDB). As of the event date on March 31, 2026, BlackRock beneficially owns 4,578,650 shares of common stock, representing 4.7% of the company. This filing marks a transition to a position below the 5% reporting threshold, as indicated by the 'Item 5' checkbox confirming the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities. BlackRock maintains sole voting power over 4,515,473 shares and sole dispositive power over the full 4,578,650 shares. The shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Various subsidiaries under BlackRock, Inc. are listed as having interests in the securities, though no single individual's interest exceeds five percent of the total outstanding common shares.